A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the call.
Dial-in numbers:
Please dial in 15 minutes prior to the live call.
Belgium 0800 389 13
France 0805 102 319
Netherlands 0800 949 4506
United States 1 866 270 1533
International 1 412 317 0797
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in
For further information, please contact:
+1 518 424 4980
bdelgiacco@argenx.com
Joke Comijn,
+32 (0)477 77 29 44
+32 (0)9 310 34 19
jcomijn@argenx.com
Source: argenx SE
2020 GlobeNewswire, Inc., source